BRPI0608885A2 - composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica - Google Patents

composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica

Info

Publication number
BRPI0608885A2
BRPI0608885A2 BRPI0608885A BRPI0608885A BRPI0608885A2 BR PI0608885 A2 BRPI0608885 A2 BR PI0608885A2 BR PI0608885 A BRPI0608885 A BR PI0608885A BR PI0608885 A BRPI0608885 A BR PI0608885A BR PI0608885 A2 BRPI0608885 A2 BR PI0608885A2
Authority
BR
Brazil
Prior art keywords
sdz
compound
pharmaceutical
pharmaceutical composition
packaging
Prior art date
Application number
BRPI0608885A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhu Tianmin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0608885A2 publication Critical patent/BRPI0608885A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0608885A 2005-03-07 2006-02-22 composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica BRPI0608885A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65937805P 2005-03-07 2005-03-07
PCT/US2006/006125 WO2006096325A1 (en) 2005-03-07 2006-02-22 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin

Publications (1)

Publication Number Publication Date
BRPI0608885A2 true BRPI0608885A2 (pt) 2017-02-21

Family

ID=36572419

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608885A BRPI0608885A2 (pt) 2005-03-07 2006-02-22 composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica

Country Status (9)

Country Link
US (1) US7241771B2 (enExample)
EP (1) EP1856131A1 (enExample)
JP (1) JP2008533007A (enExample)
CN (1) CN101137659A (enExample)
AU (1) AU2006221024A1 (enExample)
BR (1) BRPI0608885A2 (enExample)
CA (1) CA2602010A1 (enExample)
MX (1) MX2007010892A (enExample)
WO (1) WO2006096325A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
PE20070748A1 (es) * 2005-12-07 2007-08-08 Wyeth Corp Proceso ajustable a escala para la preparacion de un 42-ester de rapamicina a partir de un boronato de 42-ester de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
JP5985474B2 (ja) * 2010-08-04 2016-09-06 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CN103360411B (zh) * 2013-07-17 2015-09-30 成都雅途生物技术有限公司 依维莫司结晶提纯方法
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3061907A1 (en) 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
CN116813642B (zh) * 2023-06-29 2024-04-19 浙江康润制药有限公司 一种依维莫司纯化方法
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NO921449L (no) 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
JPH06502659A (ja) 1991-05-31 1994-03-24 ファイザー　インク 免疫抑制剤としてのラパマイシンプロドラッグの使用
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5516770A (en) 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
CA2319131A1 (en) * 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6331547B1 (en) * 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
JP2004509898A (ja) * 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6680330B2 (en) * 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) * 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c

Also Published As

Publication number Publication date
CN101137659A (zh) 2008-03-05
US20060199834A1 (en) 2006-09-07
US7241771B2 (en) 2007-07-10
MX2007010892A (es) 2007-12-05
JP2008533007A (ja) 2008-08-21
WO2006096325A1 (en) 2006-09-14
AU2006221024A1 (en) 2006-09-14
CA2602010A1 (en) 2006-09-14
EP1856131A1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ITMI20050728A1 (it) Formulazione innovativa
BRPI0511900A (pt) composições farmacêuticas
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
NO20055686D0 (no) Sammensetning
EP1719409A4 (en) INSECTICIDE COMPOSITION
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
DK1741339T3 (da) Pesticid sammensætning
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
DK1793692T3 (da) Antimikrobiel sammensætning
BRPI0610124A2 (pt) composição de resina de polipropileno
DE602006020863D1 (de) Antimikrobielle zusammensetzung
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DE502006001779D1 (de) Allylorganopolysiloxane aufweisende vernetzbare zusammensetzungen
BRPI0614413A2 (pt) composto, e, composição farmacêutica
EP1867699A4 (en) MEANS OF PREVENTING WEAKNESS
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
ATE452628T1 (de) Anthelminthische zusammensetzung
BRPI0614412A2 (pt) composto, e, composição farmacêutica
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
BRPI0810009A2 (pt) Composto, composição farmacêutica, e, intermediário sintético

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070124816/RJ DE 05/09/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 DA RPI 2119 DE 19/08/2011 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 DA RPI 2174 DE 04/09/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0

B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: REPUBLICACAO DO DESPACHO 6.8 DA RPI 2390 DE 25/10/2016 POIS O MESMO CONTINHA ERRO NO NUMERO DE REFERENCIA DA RPI A SER ANULADO. O DESPACHO 6.7 DA RPI 2133 DE 22/11/2011 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0

B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]